EDSA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

-0.450

-6.25%

-0.453

+51.11%

-0.450

+80%

Estimates Revision

The market is revising No Change the revenue expectations for Edesa Biotech, Inc. (EDSA) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -42.42%.

EPS Estimates for FY2026

Revise Upward

+0.37%

In Past 3 Month

Stock Price

Go Down

-42.42%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

Current: 0.000

Low

5.00

Averages

5.00

High

5.00

H.C. Wainwright

Yi Chen

initiated

2025-06-27

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-06-27

initiated

Reason

H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech with a Buy rating and $5 price target. Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company's lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.

Lucid Capital

Dev Prasad

Buy

initiated

2025-05-23

Reason

Lucid Capital

Dev Prasad

Price Target

2025-05-23

initiated

Buy

Reason

Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

$21

2025-03-13

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

$21

2025-03-13

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Edesa Biotech Inc (EDSA.O) is -0.84, compared to its 5-year average forward P/E of -2.60. For a more detailed relative valuation and DCF analysis to assess Edesa Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.60

Current PE

-0.84

Overvalued PE

-1.09

Undervalued PE

-4.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.20

Current EV/EBITDA

0.19

Overvalued EV/EBITDA

0.95

Undervalued EV/EBITDA

-1.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.23

Current PS

0.00

Overvalued PS

9.39

Undervalued PS

-2.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EDSA News & Events

Events Timeline

No data

News

9.5

2025-12-14SeekingAlpha

Edesa Biotech Reports GAAP EPS of -$1.27, Exceeding Estimates by $0.51

1.0

2025-10-31Newsfilter

Edesa Biotech Reveals Schedule for Upcoming Conferences

9.0

2025-10-28NASDAQ.COM

Edesa Biotech Announces Encouraging Phase 3 Outcomes for Paridiprubart in ARDS

People Also Watch

Frequently Asked Questions

What is Edesa Biotech Inc (EDSA) stock price today?

The current price of EDSA is 1.5 USD — it has decreased -0.66 % in the last trading day.

What is Edesa Biotech Inc (EDSA)'s business?

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

What is the price predicton of EDSA Stock?

What is Edesa Biotech Inc (EDSA)'s revenue for the last quarter?

Edesa Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Edesa Biotech Inc (EDSA)'s earnings per share (EPS) for the last quarter?

Edesa Biotech Inc. EPS for the last quarter amounts to -0.32 USD, increased 6.67 % YoY.

What changes have occurred in the market's expectations for Edesa Biotech Inc (EDSA)'s fundamentals?

How many employees does Edesa Biotech Inc (EDSA). have?

Edesa Biotech Inc (EDSA) has 17 emplpoyees as of January 10 2026.

What is Edesa Biotech Inc (EDSA) market cap?

Today EDSA has the market capitalization of 12.50M USD.